JP2020503330A - チアネプチンシュウ酸塩および多形 - Google Patents

チアネプチンシュウ酸塩および多形 Download PDF

Info

Publication number
JP2020503330A
JP2020503330A JP2019535330A JP2019535330A JP2020503330A JP 2020503330 A JP2020503330 A JP 2020503330A JP 2019535330 A JP2019535330 A JP 2019535330A JP 2019535330 A JP2019535330 A JP 2019535330A JP 2020503330 A JP2020503330 A JP 2020503330A
Authority
JP
Japan
Prior art keywords
tianeptine
crystalline
oxalate
monooxalate
anhydrous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019535330A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020503330A5 (cg-RX-API-DMAC7.html
Inventor
ステファノ ルカ ジャフレーダ，
ステファノ ルカ ジャフレーダ，
エンリコ モデナ，
エンリコ モデナ，
セレーナ ファブローニ，
セレーナ ファブローニ，
ミケーレ キアルッチ，
ミケーレ キアルッチ，
マーク ティー． エドガー，
マーク ティー． エドガー，
Original Assignee
トニックス ファーマ ホールディングス リミテッド
トニックス ファーマ ホールディングス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トニックス ファーマ ホールディングス リミテッド, トニックス ファーマ ホールディングス リミテッド filed Critical トニックス ファーマ ホールディングス リミテッド
Publication of JP2020503330A publication Critical patent/JP2020503330A/ja
Publication of JP2020503330A5 publication Critical patent/JP2020503330A5/ja
Priority to JP2022180549A priority Critical patent/JP2023001340A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
JP2019535330A 2016-12-28 2017-12-28 チアネプチンシュウ酸塩および多形 Pending JP2020503330A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022180549A JP2023001340A (ja) 2016-12-28 2022-11-10 チアネプチンシュウ酸塩および多形

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662439533P 2016-12-28 2016-12-28
US62/439,533 2016-12-28
PCT/IB2017/001709 WO2018122606A1 (en) 2016-12-28 2017-12-28 Tianeptine oxalate salts and polymorphs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022180549A Division JP2023001340A (ja) 2016-12-28 2022-11-10 チアネプチンシュウ酸塩および多形

Publications (2)

Publication Number Publication Date
JP2020503330A true JP2020503330A (ja) 2020-01-30
JP2020503330A5 JP2020503330A5 (cg-RX-API-DMAC7.html) 2021-02-04

Family

ID=61283255

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019535330A Pending JP2020503330A (ja) 2016-12-28 2017-12-28 チアネプチンシュウ酸塩および多形
JP2022180549A Pending JP2023001340A (ja) 2016-12-28 2022-11-10 チアネプチンシュウ酸塩および多形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022180549A Pending JP2023001340A (ja) 2016-12-28 2022-11-10 チアネプチンシュウ酸塩および多形

Country Status (13)

Country Link
US (2) US10449203B2 (cg-RX-API-DMAC7.html)
EP (1) EP3562812A1 (cg-RX-API-DMAC7.html)
JP (2) JP2020503330A (cg-RX-API-DMAC7.html)
CN (1) CN110418785A (cg-RX-API-DMAC7.html)
AU (1) AU2017385958B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019013244A2 (cg-RX-API-DMAC7.html)
CA (1) CA3048324A1 (cg-RX-API-DMAC7.html)
IL (1) IL267708A (cg-RX-API-DMAC7.html)
MX (1) MX2019007891A (cg-RX-API-DMAC7.html)
MY (1) MY199385A (cg-RX-API-DMAC7.html)
NZ (1) NZ754797A (cg-RX-API-DMAC7.html)
WO (1) WO2018122606A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201904185B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY199385A (en) * 2016-12-28 2023-10-25 Tonix Pharma Holdings Ltd Tianeptine oxalate salts and polymorphs
WO2022197719A1 (en) 2021-03-15 2022-09-22 Tonix Pharmaceuticals Holding Corp. Tianeptine oxalate and naloxone combination for the treatment of major depressive disorder

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2635461A1 (fr) * 1988-08-18 1990-02-23 Adir Utilisation de derives tricycliques pour l'obtention de medicaments destines au traitement du stress
FR2810979A1 (fr) * 2000-06-29 2002-01-04 Adir Nouveaux derives de diphenyluree, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20100112051A1 (en) * 2008-10-31 2010-05-06 Hector Guzman Tianeptine sulfate salt forms and methods of making and using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3758528A (en) * 1970-03-13 1973-09-11 Science Union & Cie Tricyclic compounds
US5405842A (en) 1994-01-28 1995-04-11 Silverman; Bernard A. Treatment of steroid dependent asthmatics
FR2791891A1 (fr) 1999-04-07 2000-10-13 Adir Utilisation de la tianeptine pour l'obtention de medicaments destines au traitement des pathologies de la neurodegenerescence
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US9314469B2 (en) 2008-05-05 2016-04-19 Tonix Pharma Holdings Limited Method for treating neurocognitive dysfunction
MY199385A (en) * 2016-12-28 2023-10-25 Tonix Pharma Holdings Ltd Tianeptine oxalate salts and polymorphs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2635461A1 (fr) * 1988-08-18 1990-02-23 Adir Utilisation de derives tricycliques pour l'obtention de medicaments destines au traitement du stress
FR2810979A1 (fr) * 2000-06-29 2002-01-04 Adir Nouveaux derives de diphenyluree, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20100112051A1 (en) * 2008-10-31 2010-05-06 Hector Guzman Tianeptine sulfate salt forms and methods of making and using the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
OROLA, LIANA ET AL.: "The effect of pH on polymorph formation of the pharmaceutically active compound TIANEPTINE", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. Vol.432, No.1-2, JPN6021051893, 2012, pages 50 - 56, ISSN: 0004999143 *
小嶌隆史: "医薬品開発における結晶性選択の効率化を目指して", 薬剤学, vol. 68, no. 5, JPN6009053757, 1 September 2008 (2008-09-01), pages 344 - 349, ISSN: 0004999144 *
浅原 照三, 溶剤ハンドブック, JPN6011026738, 1985, pages 47 - 51, ISSN: 0004999145 *

Also Published As

Publication number Publication date
AU2017385958A1 (en) 2019-07-11
MX2019007891A (es) 2019-12-16
US20180338984A1 (en) 2018-11-29
BR112019013244A2 (pt) 2019-12-24
EP3562812A1 (en) 2019-11-06
CA3048324A1 (en) 2018-07-05
US20200276208A1 (en) 2020-09-03
JP2023001340A (ja) 2023-01-04
NZ754797A (en) 2022-05-27
US10449203B2 (en) 2019-10-22
MY199385A (en) 2023-10-25
ZA201904185B (en) 2021-10-27
AU2017385958B2 (en) 2021-12-02
WO2018122606A1 (en) 2018-07-05
CN110418785A (zh) 2019-11-05
IL267708A (en) 2019-08-29
US10946027B2 (en) 2021-03-16

Similar Documents

Publication Publication Date Title
JP4996631B2 (ja) 無水結晶形態のＮ−［１−（２−エトキシエチル）−５−（Ｎ−エチル−Ｎ−メチルアミノ）−７−（４−メチルピリジン−２−イル−アミノ）−１Ｈ−ピラゾロ［４，３−ｄ］ピリミジン−３−カルボニル］メタンスルホンアミド
JP2021527043A (ja) 新規の塩および結晶
JP5899214B2 (ja) ４−［−２−［［５−メチル−１−（２−ナフタレニル）−１ｈ−ピラゾール−３−イル］オキシ］エチル］モルホリン塩酸塩の固体形態
JP2023001340A (ja) チアネプチンシュウ酸塩および多形
AU2023395880A1 (en) Crystalline melanocortin subtype-2 receptor (mc2r) antagonist
JP7496440B2 (ja) Ｔｒｋａ阻害剤
JP2020532510A (ja) 化合物の塩及びその結晶形態
CN101175758B (zh) N-[1-(2-乙氧基乙基)-5-(N-乙基-N-甲基氨基)-7-(4-甲基吡啶-2-基-氨基)-1H-吡唑并[4,3-d]嘧啶-3-羰基]甲磺酰胺的无水结晶形式
HK40016628A (en) Tianeptine oxalate salts and polymorphs
CN109912509B (zh) 一种雄性激素受体抑制剂的晶型及其制备方法
WO2025237212A1 (zh) 一种嘧啶衍生物葡甲胺盐及其晶型
JP2020529972A (ja) フェニルピリミドン化合物の塩、結晶多形並びにその医薬組成物及び使用
CN117510490A (zh) 一种稠合氮杂萘烷类衍生物的晶型及其制备方法
CN115433171A (zh) 非索替尼固体形式及其制备方法
CN116239598A (zh) 一种酮咯酸与哌嗪共晶及其制备方法
HK1116485B (en) Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
CN105473547A (zh) 阿戈美拉汀和磺酸的新复合物、其制备方法和包含其的药物组合物
HK1145148A1 (en) Solvate and crystalline forms of carbamoyl-cyclohexane derivatives
HK1145148B (en) Solvate and crystalline forms of carbamoyl-cyclohexane derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201217

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221110

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221110

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20221121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221219

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230112

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230113

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230303

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230307